Skip to content

Study for Atrial Fibrillation Reduction (SAFARI)

Study for Atrial Fibrillation Reduction (SAFARI)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00267137
Enrollment
540
Registered
2005-12-20
Start date
2002-09-30
Completion date
2006-07-21
Last updated
2025-02-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation, Bradycardia

Keywords

Pacemaker, Atrial Fibrillation/Therapy

Brief summary

Atrial fibrillation (AF), which is the name for rapid beats in the upper chambers of the heart, is the world's most common kind of irregular heart beat. People with AF experience symptoms such as heart palpitations (a racing or pounding feeling in the chest), shortness of breath, dizziness, fatigue or weakness. Although AF can occur in otherwise healthy people for no apparent reason, it is sometimes associated with high blood pressure, heart disease or lung problems. The purpose of the SAFARI trial is to study the effectiveness of pacing algorithms in the upper chamber of the heart for patients who have both AF and bradycardia (slow heart beat).

Interventions

DEVICEPacing Algorithms

Sponsors

Medtronic Cardiac Ablation Solutions
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Subjects with a slow heartbeat who are in need of dual chamber pacing (pacing in both the atrium and ventricle). * Subjects who have experienced at least two episodes of rapid heart beats three months prior to enrollment.

Exclusion criteria

* Subjects who have a history of permanent (chronic) or persistent (non self-terminating) atrial fibrillation. * Subjects with atrial fibrillation due to reversible cause, (e.g. thyroid disease, pericarditis, post-surgery, alcohol abuse). * Subjects with a history of one or more cardioversions (changing an abnormal heart rhythm into a normal one by either using medication or by the application of an electric shock) six months prior to enrollment.

Design outcomes

Primary

MeasureTime frame
Safety/Efficacy

Secondary

MeasureTime frame
Various

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026